Breast cancer claims approximately 670,000 lives each year, making it a significant global health challenge. According to data from the World Health Organization (WHO), breast cancer was the most common type of cancer among women in 157 out of 185 countries in 2022. With over 2 million women diagnosed annually, early detection and targeted treatment are crucial in combating this deadly disease. The US Food and Drug Administration (FDA) has approved the use of Kisqali, also known as ribociclib, in combination with hormone therapy for early-stage breast cancer patients. This approval provides a new treatment option for patients concerned about cancer recurrence. Ribociclib is a selective cyclin-dependent kinase inhibitor that works by targeting specific proteins involved in cancer cell growth and division. Administered orally, Kisqali is typically prescribed for three weeks followed by a one-week break, to be continued for three years. The recommended daily dose is 400 mg, which can be taken with or without food.Kisqali: Possible Side Effects

Kisqali medication may cause common side effects such as low white blood cell count or neutropenia, which happens when there are reduced levels of neutrophils in the blood. Neutrophils are crucial for battling infections in the body. Another potential side effect of Kisqali is liver-related problems and interstitial lung disease/pneumonitis.

Detecting Early Signs of Breast Cancer: Signs not to overlook